Document Detail

Radioactive iodine in the treatment of type-2 amiodarone-induced thyrotoxicosis.
MedLine Citation:
PMID:  18595575     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Amiodarone-induced thyrotoxicosis (AIT) is usually classified into two types: type 1, in which a high iodine content triggers the autonomous production of thyroid hormone; and type 2, in which destructive thyroiditis causes the release of preformed thyroid hormone. AIT is a difficult management problem that sometimes requires ablative thyroid therapy. The use of radioactive iodine (RAI) therapy in patients with type-1 AIT who had a 24-hour radioactive iodine uptake (RAIU) value of >10% has been previously reported. Despite its documented efficacy at usual doses (10-30 mCi) in patients with type-1 AIT, the efficacy of RAI in those with type-2 AIT has never been questioned, because type-2 patients usually have low RAIU. We thought that high adjusted-dose RAI might be an attractive alternative to thyroid gland ablation in patients with type-2 AIT. PATIENTS AND METHODS: Four patients with type-2 AIT who required thyroid ablation were included in the study. These individuals were either poor candidates for surgery or had refused surgery. The size of the thyroid gland in all subjects was within normal limits, and each thyroid was characterized by a homogenous echotexture on ultrasonography, the absence of vascularity on Doppler sonography, a low (<4%) 24-hour RAIU value and the absence of thyroid autoantibodies-all of which are characteristic of type-2 AIT. RESULTS: The patients were initially treated with thionamides and glucocorticoids. All patients except one achieved euthyroidism before RAI therapy. All four patients received one dose of RAI (range 29-80 mCi) and followed up for 12 months. No exacerbation of thyrotoxicosis was noted after RAI therapy. Hypothyroidism (in three patients) or euthyroidism (in one patient) was achieved in first six months. CONCLUSIONS: In patients with type-2 AIT, RAI treatment may be the therapy of choice for thyroid gland ablation.
Alptekin Gursoy; Neslihan Bascil Tutuncu; Arzu Gencoglu; Cuneyd Anil; Asli Nar Demirer; Nilgun Guvener Demirag
Related Documents :
11436965 - Are autoantibodies present in patients with subacute and chronic urticaria?
3681445 - Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patient...
67035 - Comparison of diagnostic accuracy of different peripheric parameters of thyroid function.
9255265 - A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and f...
24283825 - Fatigue in multiple sclerosis is not due to sleep apnoea.
22852095 - Cognition, behavior, and respiratory function in amyotrophic lateral sclerosis.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of the National Medical Association     Volume:  100     ISSN:  0027-9684     ISO Abbreviation:  J Natl Med Assoc     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-07-03     Completed Date:  2008-09-04     Revised Date:  2009-08-05    
Medline Journal Info:
Nlm Unique ID:  7503090     Medline TA:  J Natl Med Assoc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  716-9     Citation Subset:  IM    
Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Amiodarone / adverse effects*
Anti-Arrhythmia Agents / adverse effects*
Iodine Radioisotopes / administration & dosage*
Middle Aged
Thyrotoxicosis / chemically induced*,  diagnosis,  radiotherapy*
Treatment Outcome
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Iodine Radioisotopes; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nasal rhinosporidiosis.
Next Document:  Intestinal ischemia in systemic lupus erythematosus.